Healthcare

Global Proliferative Vitreoretinopathy Market

April 8, 2020
ID: SR/HC-35
Format:Pdf
Pages:220

Global Proliferative Vitreoretinopathy Market- By Drug Type (PRM-167, XOMA-089, Others), By End- Use (Hospitals, Clinics, Ambulatory Surgical Centers, Others), and By Region (North America, Europe, Asia Pacific, South America, and Middle East, & Africa)- Global forecast from 2020-2027.

Description

Global Proliferative Vitreoretinopathy Market Overview

Proliferative vitreoretinopathy refers to retinal detachment behind the rear surface of the retina is a common eye disease that occurs due to the failure of the reset operation. Its pathogenesis is the retinal surface and the vitreous body behind extensive fiber proliferation film shrinkage caused by pulling retinal detachment. Fibrous proliferation membrane is mainly composed of pigment epithelial cells, glial cells, fibroblasts, fibroblasts, and macrophages. Pigment epithelial cells play an essential role in the occurrence and development of proliferative vitreoretinopathy. It is not only the primary cell for the formation and contraction of proliferative membranes, but also can produce stimulating factors. That attracts fibrocytes and fibroblasts to participate in the proliferation of membrane Formation.

Global Proliferative Vitreoretinopathy Market Insights

The global Proliferative Vitreoretinopathy market is fueling with a propelling CAGR in the forecast period from 2020-2027. The rising old age population, failure in the surgery of rhegmatogenous retinal detachment (RRD). Other causes of illness such as excessive condensation, coagulation, trauma, high retinal tear, long-term retinal detachment, multiple intraocular surgeries, ocular trauma, and endophthalmitis psychosis are drivers of the market of Proliferative Vitreoretinopathy.

The formation of PVR involves a variety of cytokines, including platelet-derived growth factor (PDGF), blood vessels Endothelial growth factor, hepatocyte growth factor, transforming growth factor, epidermal growth factor, tumor necrosis factor, connective tissue growth factor, etc. The common symptoms of Proliferative Vitreoretinopathy are it causes a degree of vision loss, or visual field loss may occur. Thus, B-mode ultrasound and fundus fluorescein angiography can confirm the diagnosis of proliferative vitreoretinopathy.

Moreover, B-mode ultrasound done to produces a cross-sectional view of the eye and the orbit. When eye media is hazy due to cataract or any corneal opacity, then it is commonly used to see inside the eye.

Whereas, fundus fluorescein angiography (FFA) is a technique that uses the fluorescent light emitted by the intravenous injection of fluorescein to circulate the blood in the eye, and uses a camera equipped with a unique filter combination to record the dynamic changes of the fundus honestly. It breaks through the previous method of static observation of the fundus with ophthalmoscopes and other instruments. It has become one of the critical inspection methods for studying eye tissue anatomy, physiopathology, diagnosis and differential diagnosis, treatment, and prognosis.

Growth Driver

Old age population

Proliferative Vitreoretinopathy caused by retinal detachment pulling, rhegmatogenous retinal detachment is postoperative complications, one which majorly occurs in the old age. The cataract or haziness when it occurs inside the eyes and also, eyes with huge retinal holes have a significantly increased chance of PVR.

Technology advancement

The advancement in technology in the healthcare industry has improved the surgery of PVR. Therefore, the primary treatment for PVR is surgical treatment, drug therapy, and FFD. Also, injecting slowly dissolving glucocorticoids into the vitreous can provide a long-acting therapeutic dose without systemic side effects.

By Drug Type Segmental Analysis

Based on drug type, the global Proliferative Vitreoretinopathy market distributed into PRM-167, XOMA-089, Others. The XOMA-089 has dominated the largest market of the global Proliferative Vitreoretinopathy market. Intravitreal injection of XOMA 089 reduced the clinical stage and severity of PVR, including the severity of retinal detachment and formation of the intraocular membrane in both dose and time-dependent manner.

Moreover, a single injection of XOMA 089 is as efficient in inhibiting PVR as a weekly injection of XOMA 089 at the same dose level. The XOMA 089-mediated changes within retinal compartments characterized by decreased fibrosis, degeneration, and detachment. Final concentrations of XOMA 089 in rabbit vitreous humor showed sustained levels of exposure, and the peak concentrations of XOMA 089 in peripheral blood delayed and significantly lower than those of eyes.

By End-Use Segmental Analysis

Based on end-use, the global Proliferative Vitreoretinopathy market distributed into Hospitals, Clinics, Ambulatory Surgical Centers, Others. The hospital’s segment holds the largest market share in the global Proliferative Vitreoretinopathy market. The hospitals have the technologies, equipment, and other methods for the treatment of the Proliferative Vitreoretinopathy. Drugs such as XOMA 089 and PRM-167 majorly used in the hospitals for the treatment proliferative vitreoretinopathy. Therefore, hospitals have dominated the market share for the global proliferative vitreoretinopathy market and will continue to maintain its share in the future as well.

By Region Segmental Analysis

Based on geography, the global Proliferative Vitreoretinopathy market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America will be expecting to witness the highest growth during the forecast period from 2020-2027. North America captures the largest share in the proliferative vitreoretinopathy market. The robust healthcare facilities, continuous investment in research and development, advance technology, favorable government policies, and emerging healthcare infrastructure are booming the proliferative vitreoretinopathy market in North America.

Competitor Analysis

Companies such as Novartis AG, Promedior, Inc., RXi Pharmaceuticals Corp., Allergan plc, Regeneron Pharmaceuticals, Inc., Genentech, Inc., among others, are key players in the global Proliferative Vitreoretinopathy market.

Key Stakeholders

Market research and consulting firms
Industry associations
Global Proliferative Vitreoretinopathy manufacturing companies
Research organizations and consulting companies’ gases and equipment
Regulatory bodies

Recent Developments

In September 2021, Novartis signed a deal with Britain’s NHS to use the new anti-cholesterol drug Leqvio.
In February 2020, Roche announced the acquisition of Promedior, Inc. to get the full rights of Promedior’s entire portfolio of molecules for serious fibrotic diseases.
In June 2021, Genentech’s drug, intravenous Actemra®, received FDA emergency use authorization to treat COVID-19 in hospitalized adults and children.

Scope of the report

Report Attribute	Details
Market size value in 2020	USD 470.2 Million
Revenue forecast in 2027	USD 671.42 million
Growth Rate	CAGR of 4.23% from 2020 to 2027
Historical data	2017-2019
Forecast period	2021 – 2027
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	Novartis AG, Promedior, Inc., Regeneron Pharmaceuticals, Inc., RXi Pharmaceuticals Corp., Allergan plc, Genentech, Inc.

The objective of the Research

Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
Market Trend and Economic Factors Analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
Market Segmental Analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.

Market Modelling

By Drug Type

PRM-167
XOMA-089
Others

By End-user

Hospitals
Clinics
Ambulatory Surgical Centers
Others

By Region

Europe
North America
Asia Pacific
South America
Middle East & Africa

Table Of Contents

Methodology

Request Sample

Frequently Asked Questions (FAQ):

What is a Proliferative vitreoretinopathy?

Proliferative vitreoretinopathy refers to retinal detachment behind the rear surface of the retina, which is a common eye disease that occurs due to the failure of the reset operation.

What is the size of the Proliferative vitreoretinopathy Market?

The Global Proliferative vitreoretinopathy Market’s size is valued at USD 470.2 Million in 2020 and will reach USD 671.42 million by 2027.

What is the growth rate of the Proliferative vitreoretinopathy Market?

The growth rate of the Proliferative vitreoretinopathy Market is 4.23% during the forecast period.

Who are the end-users of the Proliferative vitreoretinopathy Market products?

Hospitals, Clinics, Ambulatory Surgical Centers, Others are the end-users of the Proliferative vitreoretinopathy Market products.

What is the competitive landscape of the Proliferative vitreoretinopathy Market?

Novartis AG, Promedior, Inc., Regeneron Pharmaceuticals, Inc., RXi Pharmaceuticals Corp., Allergan plc, Genentech, Inc., among others, are the key players in the global proliferative vitreoretinopathy market.

Select License

We Accept

Analyst support

After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.

Customer satisfaction

According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.

Inimitable expertise

Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.

Assured quality

We have created a systematic way to determine standards and satisfy your expectations.

Instant delivery

Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.

Privacy policy

We understand the inkling of your privacy, we will never misuse your email address.

Custom research service

We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.

Quality & accuracy

We provide you with the accurate quality of the customized study of an exclusive report according to your research need.

Data visualization

As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.

Information security

We truly respect your privacy and promise to keep your personal and confidential information safe and secure.